Should a Provider Be on Site During Chemotherapy Administration?
In clinics and oncology floors across the country, IV pumps are infusing, chemotherapy is administered through IV push, and nurses are moving swiftly from one patient to the next. Administering chemotherapy is a complex, in-depth procedure that requires training, education, and a level of experience beyond that of the standard healthcare professional. However, even the best oncology nurses need the support of their team members and the administration to provide the safest possible care environments for their patients.
Protein May Explain Chemo Resistance in Patients With BRCA2 Mutations
Researchers have discovered a protein that may lead to a new way to prevent resistance and improve outcomes for patients whose cancers have a BRCA2 mutation. The findings were reported in Molecular Cell.
What Precautions and Recommendations Are Necessary for Patients Receiving Oral Chemotherapy in the Home?
So far, 2017 has seen an incredible amount of U.S. Food and Drug Administration approvals for new agents and indications. Biotherapy and targeted agents represent many of the newly approved treatment options—a great deal of which are offered in oral form, increasing the opportunity for patients to receive treatment at home.
Time Is Short When Addressing Hypersensitivity Reactions to Chemotherapy
Between administering antineoplastic agents, monitoring patient vitals, and preparing patients for treatment, oncology nurses are required to balance their attention between many intricate tasks. Chief among the division of duties is that oncology nurses closely monitor their patients for hypersensitivity reactions (HSRs) to prescribed agents.
How Safe and Effective Is Scalp Cooling for Chemotherapy-Induced Alopecia?
Chemotherapy-induced alopecia has been reported by 77% of patients as the most-feared side effect of cancer treatment. In fact, as many as 10% of women say they would consider refusing chemotherapy or choosing a less effective treatment to avoid losing their hair.
FDA Approves Liposome-Encapsulated Combination of Daunorubicin-Cytarabine for Patients With AML
On August 3, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to a liposome-encapsulated combination of daunorubicin and cytarabine (Vyxeos™, Jazz Pharmaceuticals, Inc.) for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two types of AML having a poor prognosis.
Safely Provide Outpatient Care to Patients Receiving Hematopoietic Stem Cell Transplantations
High-dose chemotherapy with hematopoietic stem cell support is a well-established treatment for many hematologic malignancies. This treatment can be a difficult journey for patients and families. Historically, patients have been treated in a traditional hospital setting in anticipation of severe side effects, including mucositis, febrile neutropenia, thrombocytopenia, and pulmonary, renal, and hepatic complications. Patients can remain profoundly immunosuppressed for months while recovering from transplant. However, better supportive care in recent years has allowed many centers to move all or a portion of their transplant care into an outpatient setting.
Who Is Monitoring Your Infusions for Administration Safety?
Inquiries received in the ONS clinical inbox often ask about various responsibilities of nurses who hold an ONS chemotherapy provider card and have been deemed competent to administer cancer treatments within their practice setting.
Palonosetron HCL Is a Preferred Treatment for Moderately Emetogenic Chemotherapies
Chemotherapy-induced nausea and vomiting (CINV) is an adverse event (AE) associated with cancer therapies that healthcare providers often underestimate. CINV can interfere with treatment compliance and adherence, and patients who experienced CINV in the first cycle of chemotherapy are almost four times more likely to experience it during subsequent treatment cycles.
Chemotherapy Use Near the End of Life Is More Common in United States
National guidelines suggest that the use of chemotherapy near end of life (EOL) is aggressive and is associated with poorer patient quality of life. In addition, Medicare payments for outpatient chemotherapy have decreased since around 2005–2006. In a recent study presented at the 2017 ASCO Annual Meeting, researchers evaluated the impact of U.S. payment reform and guidelines on chemotherapy use at EOL, comparing chemotherapy use at EOL in the United States and other countries.
Patients Are Equally Satisfied With Phone Calls and In-Person Consultations Before Chemotherapy
Previous research has indicated that patient satisfaction is linked to time spent with a physician. However, long wait times and organizational issues in an outpatient setting may increase the need for alternative care models. In a study presented at the ASCO Annual Meeting, researchers assessed the use of phone calls instead of a face-to-face consultation prior to chemotherapy (CT) and the effect on patient satisfaction and quality of life.
What Special Considerations Are Needed When Setting up IV Chemotherapy?
No solid research exists regarding IV chemotherapy administration setups, because they can vary greatly based on the regimen, equipment availability, and patient status. Of the utmost importance is that the administration setup ensures chemotherapy is given safely and allows for prompt nursing intervention in the event of an adverse reaction or infiltration.
What Is ONS’s Stance on Handling Chemotherapy While Pregnant, Breastfeeding, or Trying to Conceive?
One of the questions that ONS commonly receives in the clinical inbox is whether nurses who are pregnant, breastfeeding, or trying to conceive can safely administer or handle chemotherapy and other hazardous drugs.
How Did ONS Collaborate to Shape the ASCO/ ONS Chemotherapy Safety Standards?
Standards of care are written to address safety and quality in oncology practice. When the American Society of Clinical Oncology (ASCO) and ONS recognized the need to develop chemotherapy safety standards, the two organizations came together to determine how the process of delivering chemotherapy could be made as safe as possible.